Related Experiment Video

Updated: Apr 13, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Practical recommendations for the management of hyperlipidemia

S Fischer¹, U Schatz¹, U Julius¹

¹Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.

Atherosclerosis. Supplements

|May 5, 2015

Insights

Hyperlipidemia management involves lifestyle changes and medications like statins. Genetic analysis may predict statin side effects, and drug combinations benefit patients with kidney issues.

Area of Science:

Cardiology
Metabolic Disorders
Pharmacogenomics

Background:

Hyperlipidemia, characterized by elevated cholesterol and triglycerides, is a significant risk factor for atherosclerosis.
Raised low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) are severe risk factors, while the role of high-density lipoprotein cholesterol (HDL-C) remains debated.
Accurate lipid level assessment requires fasting blood samples.

Purpose of the Study:

To review current understanding and management strategies for hyperlipidemia.
To discuss the efficacy and side effects of various lipid-lowering therapies.
To highlight advancements in personalized medicine for hyperlipidemia treatment.

Main Methods:

Review of epidemiological data and clinical trial findings on hyperlipidemia.
Analysis of pharmacological interventions, including statins, ezetimibe, and others.
Exploration of genetic factors influencing statin response and management in specific populations.

Main Results:

Lifestyle modifications (diet, exercise, weight reduction) are foundational. Statins are first-line drugs, with ezetimibe, bile acid sequestrants, fibrates, and fish oil as alternatives.
Statin use is associated with myopathies and an increased risk of diabetes mellitus.
Genetic analysis shows promise in predicting individual statin tolerance and efficacy, particularly for simvastatin.
The combination of simvastatin and ezetimibe demonstrated cardiovascular event reduction in patients with renal insufficiency (SHARP Study).

Conclusions:

Effective hyperlipidemia management requires a multi-faceted approach including lifestyle changes and pharmacotherapy.
Personalized treatment strategies, informed by genetic data, can mitigate statin-related side effects.
Combination therapy is beneficial for high-risk patients, including those with renal insufficiency.
Primary prevention of hyperlipidemia in young patients presents ongoing challenges.

Read full analysis

Abstract:

Hyperlipidemia is a risk factor for atherosclerosis. Raised low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) levels are severe risk factors for atherosclerosis. The role of high-density lipoprotein cholesterol (HDL-C) is controversial. Total cholesterol, LDL-C, HDL-C, triglycerides and lipoprotein(a) levels should be determined in a fasting state. The basis of treating hyperlipidemia remains diet, physical exercise and weight reduction. Olive oil and nuts have been shown to be beneficial. Statins remain first line drug treatment. Further treatment options are ezetimibe, bile acid sequestrants, fibrates and fish oil. Side effects of statins include myopathies and, as shown during the last years, also an increased risk of diabetes mellitus. In patients with statin-related myopathies first results of a gene analysis have been published showing a means of predicting which statin can be administered at which dose for the individual patient with least risk of side effects. Most convincing data have been shown for simvastatin. Patients with renal insufficiency have been shown to have a raised cardiovascular risk. In the SHARP Study the combination of simvastatin plus ezetimibe was effective in reducing cardiovascular events in patients with severe renal insufficiency (especially before dialysis but also in dialysis dependent patients). Important aspects of treating patients with chylomicronemia syndrome are illustrated. Treating young patients with hyperlipidemia as primary prevention remains problematic.

Keywords:

Cardiovascular risk in patients with renal insufficiency Chylomicronemia syndrome Diagnostics of myopathies Lipid-lowering therapy in special situations Raised LDL-C values Raised lipoprotein(a) levels Side effect of statins

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Lipids: Dietary Sources and Requirements

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Articles linked to this work by shared authors, journal, and citation graph.

[Brugada syndrome].

Medizinische Klinik (Munich, Germany : 1983)·2001

[Calculation of the partial function of the kidney with DMSA in pediatrics: is the evaluation of the geometric mean necessary?].

Nuklearmedizin. Nuclear medicine·2001

Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques.

Circulation·2001

Radon survey in Kalamata (Greece).

Radiation protection dosimetry·2001

Clinical cardiac and pulmonary transplantation: the Hannover experience.

Clinical transplants·2001

In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat.

Human gene therapy·2001

See all related articles